Review




Structured Review

Millipore lpl sirna 1 (sasi_hs01_00208454)
LPL and VLDLR are involved in VLDL uptake in MDA-MB-231 BC cells. A: qRT-PCR verification of LPL and VLDLR knockdown in MDA-MB-231 BC cells treated with LPL or VLDLR siRNA. LPL and VLDLR gene expression of siRNA cells is presented relative to that of the Scr siRNA control. LPL siRNAs knocked down LPL mRNA, while VLDLR siRNAs significantly reduced both VLDLR and LPL mRNAs. B: Western blot shows VLDLR protein knockdown by siRNAs. C: siRNA knockdown of LPL or VLDLR reduces DiI-VLDL uptake in MDA-MB-231 BC cells. The greatest decreases were observed in VLDLR <t>siRNA</t> <t>1</t> cells, which had the highest efficiency knockdown of both VLDLR and LPL mRNAs. DiI-VLDL uptake was reduced by heparin by all treatments except VLDLR siRNA, where the reduction from VLDL alone was not significant. P ≥ 0.05 (ns), *P < 0.05, **P < 0.01, and ***P < 0.001. D: RAP (1 µM) inhibits DiI-VLDL binding and uptake at 37°C by MDA-MB-231 cells, as visualized by confocal microscopy. DiI-VLDL (red), DAPI (blue).
Lpl Sirna 1 (Sasi Hs01 00208454), supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lpl sirna 1 (sasi_hs01_00208454)/product/Millipore
Average 90 stars, based on 1 article reviews
lpl sirna 1 (sasi_hs01_00208454) - by Bioz Stars, 2026-04
90/100 stars

Images

1) Product Images from "Endocytosis of very low-density lipoproteins: an unexpected mechanism for lipid acquisition by breast cancer cells [S] "

Article Title: Endocytosis of very low-density lipoproteins: an unexpected mechanism for lipid acquisition by breast cancer cells [S]

Journal: Journal of Lipid Research

doi: 10.1194/jlr.RA119000327

LPL and VLDLR are involved in VLDL uptake in MDA-MB-231 BC cells. A: qRT-PCR verification of LPL and VLDLR knockdown in MDA-MB-231 BC cells treated with LPL or VLDLR siRNA. LPL and VLDLR gene expression of siRNA cells is presented relative to that of the Scr siRNA control. LPL siRNAs knocked down LPL mRNA, while VLDLR siRNAs significantly reduced both VLDLR and LPL mRNAs. B: Western blot shows VLDLR protein knockdown by siRNAs. C: siRNA knockdown of LPL or VLDLR reduces DiI-VLDL uptake in MDA-MB-231 BC cells. The greatest decreases were observed in VLDLR siRNA 1 cells, which had the highest efficiency knockdown of both VLDLR and LPL mRNAs. DiI-VLDL uptake was reduced by heparin by all treatments except VLDLR siRNA, where the reduction from VLDL alone was not significant. P ≥ 0.05 (ns), *P < 0.05, **P < 0.01, and ***P < 0.001. D: RAP (1 µM) inhibits DiI-VLDL binding and uptake at 37°C by MDA-MB-231 cells, as visualized by confocal microscopy. DiI-VLDL (red), DAPI (blue).
Figure Legend Snippet: LPL and VLDLR are involved in VLDL uptake in MDA-MB-231 BC cells. A: qRT-PCR verification of LPL and VLDLR knockdown in MDA-MB-231 BC cells treated with LPL or VLDLR siRNA. LPL and VLDLR gene expression of siRNA cells is presented relative to that of the Scr siRNA control. LPL siRNAs knocked down LPL mRNA, while VLDLR siRNAs significantly reduced both VLDLR and LPL mRNAs. B: Western blot shows VLDLR protein knockdown by siRNAs. C: siRNA knockdown of LPL or VLDLR reduces DiI-VLDL uptake in MDA-MB-231 BC cells. The greatest decreases were observed in VLDLR siRNA 1 cells, which had the highest efficiency knockdown of both VLDLR and LPL mRNAs. DiI-VLDL uptake was reduced by heparin by all treatments except VLDLR siRNA, where the reduction from VLDL alone was not significant. P ≥ 0.05 (ns), *P < 0.05, **P < 0.01, and ***P < 0.001. D: RAP (1 µM) inhibits DiI-VLDL binding and uptake at 37°C by MDA-MB-231 cells, as visualized by confocal microscopy. DiI-VLDL (red), DAPI (blue).

Techniques Used: Quantitative RT-PCR, Expressing, Western Blot, Binding Assay, Confocal Microscopy



Similar Products

Image Search Results